INTRODUCTION
According to the Leukemia and Lymphoma Society of Canada, lymphomas are one of the most common malignancies, affecting approximately 8900 Canadians per year. The majority of patients (approximately 90%) are diagnosed with nonHodgkin lymphoma (NHL). Cutaneous T-cell lymphoma (CTCL) represents a heterogeneous group of extranodal NHLs characterized by the localization of neoplastic T lymphocytes to the skin. 1 The updated 2016 World Health Organization classification of primary cutaneous lymhomas, 2, 3 similar to the initial 2005 World Health Organization-European Organization for Research and Treatment of Cancer classification of primary cutaneous lymphomas 1 and the International Classification of Diseases for Oncology, third edition (ICD-O-3), 4 recognizes the following CTCL variants: mycosis fungoides (MF) (ICD-O-3 code 9700); Sezary syndrome (SS) (code 9701); mature T-cell lymphoma not otherwise specified (NOS) (code 9702); angioimmunoblastic T-cell lymphoma (code 9705); subcutaneous panniculitis-like T-cell lymphoma (code 9708); CTCL NOS (code 9709); cluster of differentiation 30 (CD30-positive T-cell lymphoproliferative disorders of the skin (codes 9714 and 9718); extranodal natural killer(NK)/T-cell lymphoma, nasal type (ENKL) (code 9719); and adult T-cell leukemia/lymphoma (ATLL) (code 9827). It is noteworthy that MF, its leukemic form (SS), and anaplastic large-cell lymphoma are the most common variants and account for approximately 80% of all CTCLs. 5 Previous epidemiologic studies of the 10 CTCL variants described above, based on the Surveillance, Epidemiology, and End Results databases, documented that, until recently, CTCL was on the rise in the United States and around the world. 4 Multiple studies have demonstrated a 3-fold increase in CTCL incidence during 1970 through 2000; however, it is noteworthy that, in the last decade, the incidence of CTCL in the United States has stabilized and is estimated to affect approximately 10.2 individuals per million population per year. 4, 6 This malignancy is more common in older individuals (ie, aged >50 years) and among males. Important differences are observed between different ethnicities, and the average age of MF/CTCL diagnosis among African Americans and Hispanics patients is significantly lower than that among Caucasians. [7] [8] [9] [10] [11] In fact, CTCL reportedly had a higher predilection for African American men, in whom this cancer typically presents with higher clinical stage at the time of diagnosis and follows a more aggressive clinical course. 7, 11, 12 Different regional variations in CTCL incidence have been reported: approximately 14 to 16 cases per million individuals per year were diagnosed in San Francisco, California, whereas only 6 or 7 cases per million individuals per year were diagnosed in Iowa during 2000 through 2009. 4 Recent studies also revealed that CTCL may occur in married couples and cluster in families. [12] [13] [14] [15] Our recent work demonstrated geographic clustering of CTCL cases in Texas. 12, 16 Specifically, based on an analysis of 1990 patients using 2 distinct population-based cancer registries, we have documented geographic clustering of patients in several communities across Texas. This included cities in which CTCL incidence rates were 5 to 20 times higher than the expected population rate. Notably, patients with this rare cancer were residing along the same streets/highways and/or streams. 12, 16 Furthermore, the analysis demonstrated that 2 densely populated, adjacent zip codes located in a desert climate near El Paso, Texas, were completely spared by CTCL during 1995 through 2010. 17 Other recent studies also suggested geographic clustering for this rare cancer in Pittsburgh, Pennsylvania, and in the Vasternorrland county of Sweden. 18, 19 The pathogenesis of MF and other variants of CTCL remains only partially understood. Multiple studies have attempted to clarify the genetic multistep carcinogenesis of CTCL. [20] [21] [22] It was noted that certain human leukocyte antigen (HLA) class II alleles (eg, HLA-DRB1*11 and DQB1*03) were associated with CTCL, 14, 23 thus suggesting that one of the molecular pathogenesis mechanisms may involve inappropriate T-cell activation through antigen presentation followed by the accumulation of neoplastic memory T cells. These combined results strongly argue for the existence of an external trigger/promoter for CTCL. It is noteworthy that several such external triggers/disease-promoting factors have been proposed and are summarized in recent review articles. [24] [25] [26] MATERIALS AND METHODS This study was conducted in accordance with the CISS-RDC-668035 and 13-SSH-MCG-3749 protocols approved by the Social Sciences and Humanities Research Council of Canada (SSHRC) and the Quebec InterUniversity Centre for Social Statistics (QICSS), respectively. In addition, in accordance with institutional policy, this study received an exemption from the McGill University Research Ethics Board.
The data on patients with CTCL in this study were obtained from the Canadian Cancer Registry (CCR), le registre qu eb ecois du cancer (LRQC), and the Canadian Vital Statistics (CVS) databases. The CCR is a dynamic database of Canadian residents from 12 Canadian provinces and territories (excluding Quebec) who were diagnosed with primary tumors from 1992 through 2013 and are alive or dead. Data for patients in Quebec were obtained from the LRQC, which is part of the r egie de l'assurance maladie du Qu ebec database. Data from the LRQC database were available only from 1992 to 2010. Data on new cases of CTCL were obtained from the CCR (2014 version), which spans the period from 1992 to 2013. Because the data from the LRQC database for Quebec were only available up to 2010, for this study, we chose to analyze the data from 1992 through 2010 to include all Canadian provinces for the same time period.
The CCR/LRQC databases provide geographic and clinical information, including patients' sex, year of diagnosis, age at the time of diagnosis, and postal code of residence as well as the ICD-O-3 code of the tumor. The CCR/LRQC databases were not able to provide data on clinical disease stage at the time of diagnosis or, unfortunately, on several other demographic characteristics, including the ethnic background of patients.
Consistent with the initial 2005 World Health Organization-European Organization for Research and Treatment of Cancer and the updated 2016 WHO classifications of primary cutaneous lymphoma, 1-3 CTCL cases were defined based on ICD-O-3 codes. 27 Primary site of skin was coded 44.0 through 44.9, and CTCL diagnoses were coded, as described above, for MF (ICD-O-3 code 9700), SS (code 9701), mature T-cell lymphoma (MTCL) NOS (code 9702), angioimmunoblastic T-cell lymphoma (code 9705), subcutaneous panniculitis-like T-cell lymphoma (code 9708), CTCL NOS (code 9709), CD30-positive T-cell lymphoproliferative disorders of the skin (codes 9714 and 9718), ENKL (code 9719); and ATLL (code 9827). 1, 4, 28 The CTLC subtypes analyzed in this study are identical to those analyzed in the landmark CTCL incidence studies conducted in the United States. 4, 29 To assess cause of mortality, we used the CVS mortality database. For cause-of-death analysis, the International Statistical Classification of Diseases and Related Health Problems, ninth revision (ICD-9) had to be used for deaths during 1992 through 1999 (codes 202.1 and 202.2 for MF and "Sezary's disease," respectively), and the corresponding 10th revision (ICD-10) was used for deaths from 2000 through 2010 (codes C84.0 and C84.8 for MF and "Sezary's disease," respectively). Note that, although the ICD-10 identifies additional CTCL subtypes, because these were not recorded in the ICD-9 version, we had to limit our analysis to MF and SS.
For incidence/mortality analyses, data on population counts nationally, per province, per city, and (for incidence analysis only) per Forward Sortation Area (FSA) (a geographic region in which all postal codes start with the same 3 characters) were obtained from the Canadian Census of Population for the years 1996, 2001, 2006, and 2011 from Statistics Canada. Note that, in Canada, postal codes consist of letters and numbers (eg, K1H 8L6), and the first 3 entries (eg, the FSA) define a region in the country, which, in this example, happens to include the Ottawa Hospital.
Mandatory Data Rounding
Several confidentiality rules apply to CCR, LRQC, and CVS data before their publication, such as random rounding of variables as absolute numbers for CTCL cases; these are indicated whenever actual case numbers are presented in tables. With regard to random rounding of tabular data, SSHRC/Statistics Canada requires rounding of each cell count, independent of other cells, to a lower or higher multiple of 5 using an unbiased, random rounding scheme in which counts are more likely to be rounded to their nearest multiple of 5. No counts 1 and <5 can be published according to the SSHRC regulation. If the numbers of cases/deaths were 1 but <5 per province/ city or FSA, then the data could not be released to protect patient confidentiality. We were able to review communities in which zero CTCL cases/deaths were documented. The raw data (not rounded numbers) were used for several analyses (as indicated) in the study. Also, regarding the subanalysis of MF and SS cases, if the difference between the total numbers of CTCL cases (based on the data describing 10 variants) and the numbers MF/SS cases in a given city was <5, then the data could not be released to avoid indirect disclosure of identifiable information to protect patient confidentiality. Indeed, the SSHRC/Statistics Canada is concerned that, by providing information on all major variants, these numbers could be subtracted from the total CTCL case numbers and inadvertently identify patients with rarer disease variants in a given geographic location, which can lead to breach of patient confidentiality.
Statistical and Mapping Analyses
Unless otherwise specified, analyses of the complete data on all patients with CTCL across Canada for the period from 1992 through 2010 are presented throughout this report. Incidence rates and 95% confidence intervals (CIs) were calculated and are reported overall, by year of diagnosis, and for specific regions identified by the mapping analysis. Unless otherwise specified, Canadian Census data from the years 1996, 2001, 2006, and 2011 were used for all population analyses. Results from the FSA geographic clustering findings were also compared with the average population counts for the indicated census years.
CIs were based on a Byar approximation to the Poisson distribution, because this calculation provides very accurate approximations to the exact Poisson probabilities, including small counts. 30 Incidence rates were plotted using a linear regression model to assess trends over time.
Geographic maps of Canada divided by FSA codes indicating the residence of patients with CTCL documented by the CCR, LRQC, and CVS databases were generated using geographic information systems software (ArcMap 10.4; Environmental Systems Research Institute, Redlands, Calif). In mapping the CCR, LRQC, and CVS results, only FSAs with populations of at least 5000 individuals based on 1996, 2001, 2006, and 2001 census data were selected to reduce erroneous false-positive hits, in which a single case of CTCL occurring within a scarcely populated FSA (<5000 residents) might have artificially inflated the incidence/mortality rate. male predominance was observed for the majority of CTCL subtypes (Table 1 and Fig. 1A ). The male-tofemale incidence rate ratio of CTCL in the Canadian population during 1992 through 2010 was 1.4:1 with a stable trend throughout this period (Fig. 1A) . The mean age of diagnosis for patients with CTCL in Canada during 1992 through 2010 was 59.4 6 21.5 years, and the individual subtypes had similar age ranges (Supporting Table 1 ; see online supporting information).
Incidence of CTCL in Canada From 1992 Through 2010
We subsequently analyzed the incidence rate of CTCL overall in Canada. The incidence rate was approximately 5.2 cases per million individuals per year in 1992, and it subsequently increased and leveled off to approximately 11 or 12 cases per million individuals per year from 1998 onward, as illustrated in Figure 1B . On the basis of our analyses, the incidence rate during 1992 through 2010 was 11.32 cases per million individuals per year (95% CI, 11.05-11.59 cases per million individuals per year) ( Table  2 ). We performed a linear regression analysis of the CTCL incidence rate and documented an increase of approximately 0. (Fig. 1C) . We also investigated the incidence rates for each of the 10 subtypes during the aforementioned period, as depicted in Figure 2 .
Geographic Distribution of CTCL Cases in Canada
The incidence rates for Canadian cities and provinces revealed interesting trends (Figs. 3, 4 and 5; and Tables 2, 3, 4 and 5). The provinces of Newfoundland and Labrador, Nova Scotia, New Brunswick, Manitoba, and Saskatchewan had significantly higher incidence rates than the national average, as indicated in Table 2 and Figure 5A . Conversely, the province of Ontario had the lowest incidence rate of 9.27 (95% CI, 8.88-9.67) cases per million individuals per year.
Next, we examined the incidence of CTCL across Canadian cities. The total number of CTCL cases, as expected, was higher in larger cities including Toronto, Montreal, Vancouver, Edmonton, and Calgary (Fig.  3A) . However, we noted that Ottawa (population, approximately 850,000) had less cases than expected (n 5 65), whereas Winnipeg (population, approximately 650,000) had more than expected (n 5 175) cases during the study period. This analysis of CTCL incidence rates by city corroborated the provincial trends. Newfoundland and Labrador, Nova Scotia, Manitoba, Saskatchewan, and Prince Edward Island all had CTCL incidences that were statistically higher than the Canadian average, as discussed above. Consistent with these findings, CTCL incidences were elevated in St. John's, Newfoundland; Saint John, New Brunswick; Moncton, New Brunswick; Regina, Saskatchewan; and Winnipeg, Manitoba ( Fig. 3B and Table 3 ). Conversely, several cities in Ontario, Quebec, and Alberta had statistically significantly lower rates of CTCL than the rest of the country (Table 3 ). It is noteworthy that Ottawa, Ontario, the fourth largest Canadian city and the main administrative center of the country, had the lowest CTCL incidence rate of all major cities (4.04 cases per million individuals per year; 95% CI, 3.11-5.14 cases per million individuals per year). The data for Ottawa were obtained from the CCR. Notably, across the river from Ottawa, the city of Gatineau, Quebec (based on data from the LRQC), also had a significantly lower This nonrandom distribution of CTCL on provincial and city scales indicates the possibility of clustering of cases in particular communities in Canada. Hence, we analyzed the incidence of CTCL in Canada by region, using FSA postal codes. Of 6685 patients, postal code information for >98% was available in the database, conferring an adequate method of analysis. FSAs with a statistically significant elevation in incidence of CTCL are listed in Table 4 and are geographically depicted in different shades of brown (depending on the incidence rate) in Figure 4 .
Although stand-alone, high-incidence FSAs may be important, it is interesting to note that, in several instances, multiple high-incidence FSAs were located geographically side-by-side. Specifically, in Newfoundland and Labrador, the high-incidence FSAs A1A and A1M were contiguous (Fig. 4A) . Similarly, B0M and B0N highincidence FSAs were adjacent and highlighted rural communities in Nova Scotia (Fig. 4C ). J08 and J1G highincidence FSAs were noted in Sherbrooke/Eastern Townships, Quebec (Fig. 4E) . On the island of Montreal, Quebec H9X, H9S, H4W, and H3Y high-incidence FSAs were highlighting old industrial areas in the south-western part of the city (Fig. 4D) . Similarly, in Winnipeg, 2 FSAs were located in the western part of the city. In Vancouver, high-incidence FSAs seemed to be scattered throughout the metropolitan area.
We also conducted incidence rate analysis to identify areas that were spared (ie, zero cases) by CTCL during 1992 through 2010. This analysis documented 8 FSAs that had a statistically significant low incidence of CTCL (Table 5 ). These FSAs are depicted in gray on the maps in Figure 4 . Not surprisingly, the majority of these communities (K1G, K2K, K2S, L4S, L4R, and M9M,) were in Ontario (6 of 8 FSAs). Three of them clustered in Ottawa (Fig. 4H) . It is noteworthy that there were no highincidence FSAs were in this city. The other 2 communities were in Quebec (J2W) and Alberta (T5Y). As alluded to above, further in-depth analyses of the highlighted high-incidence regions revealed that several of these FSAs were located in heavy industrial regions in Canadian cities. Land use maps for Montreal, Winnipeg, Oakville, and Hamilton are provided in Supporting Figures 1, 2 , and 3 (see online supporting information). Joint analysis of the distribution of high-incidence FSAs and industrial/land use maps revealed that, across Montreal, these FSAs painted/highlighted the old industrial southwestern portion of the city near the shore of the St. Lawrence Seaway (Supporting Fig. 1 ; see online supporting information). Similarly, the high-incidence FSA L8V is located adjacent to a major industrial sector in Hamilton, Ontario (Supporting Fig. 2A ; see online supporting information), whereas the nearby L6L high-incidence FSA is located in Oakville, Ontario (Supporting Fig. 2B ; see online supporting information), where many people commute to work in Hamilton. In addition, Oakville, Ontario also has a significant industrial presence, as highlighted in the figure. Furthermore, high-incidence FSAs R3K and R3B were located in industrial areas of western Winnipeg (Supporting Fig. 3 ; see online supporting information). Conversely, Ottawa has very little industrial presence (Supporting Fig. 4 ; see online supporting information).
Furthermore, where possible, we conducted an analysis of CTCL incidence by individual postal code, analyzing patient clustering on the level of streets and buildings. This enabled us to search for an additional level of case clustering within the highlighted FSAs. Unfortunately, the regulations do not allow us to present maps or specific numbers with higher resolution than the FSA. We are also not allowed to discuss individual case distribution in a given geographic area. However, it is important to highlight that, based on our analyses of cases, we observed an important additional clustering of patients within the identified FSAs (data not shown). This was most prominently noted in the R3B FSA in Winnipeg, Manitoba; the P0G FSA in Englehart, Ontario; and the B0N FSA in rural Nova Scotia, where CTCL cases were not occurring in a random, "buck shot" distribution but were clustered in specific areas within each FSA. Strikingly, in the R3B FSA, all cases were documented in the industrial area of west Winnipeg.
Within the identified high-incidence FSAs (Table  4) , we performed subanalyses of patient clinical characteristics. We observed that patients' clinical characteristics within these regions were not significantly different from those in the general population of Canadian patients with CTCL (Supporting Table 2 ; see online supporting information). Hence, based on these analyses, it does not appear that patients in the identified FSAs had an unusual distribution or an unusual variant of CTCL disease.
Subanalyses of MF, SS, and MTCL NOS Cases
Considering that MF and SS together represent >50% of CTCLs, we wanted to perform a separate subanalysis of these 2 disease variants. Furthermore, because these common variants may be misclassified as cutaneous lymphoma NOS, we wanted to include the NOS variants in this analysis, similar our previous work. 12, 16 Hence, we analyzed the data on patient reporting province and city for MF (ICD-O-3 code 9700), SS (code 9701), and MTCL NOS (code 9702) variants diagnosed during 1992 through 2010 in Canada. We also requested data for the CTCL NOS (code 9709) variant; however, because there were only 570 cases of this variant in the country, Original Article
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Cancer the CCR and the LRQC declined to release these findings in accordance with the confidentiality regulations described above. Because there were fewer cases, we were only allowed to perform the subanalyses at the levels of provinces and cities, and not FSAs. Similarly, because the numbers of patients with MF/SS were small in the province of Quebec (ie, n 5 210) (Supporting Table 3 ; see online supporting information), the LRQC did not release incidence data by city for these CTCL variants. Similarly, because of the small numbers of patients with MTCL NOS, incidence findings by city could not be released by the CCR/ LRQC.
Newfoundland and Labrador, New Brunswick, and Manitoba had higher CTCL incidences than the rest of Canada, as highlighted above (Table 2 ). An analysis of the incidence of MF, SS, and MTCL NOS similarly highlighted high incidence rates of these lymphoma variants in these jurisdictions (Supporting Table 3 ; see online supporting information). It is noteworthy that 9 provinces that provided data to the CCR coded a significant number of MF/SS cases and relatively few MTCL NOS cases, in Quebec, which follows a different procedure and submits its data to the LRQC, the reverse trend was observed. In this province, substantial numbers (500 cases) of patients with MTCL NOS were reported, in contrast to the low numbers (210 cases) of combined MF/SS (Supporting Table 3 ; see online supporting information).
Furthermore, the distribution of the reported MF/ SS cases at the city level was also consistent with abovedescribed findings for all variants. The cities of St. John's, Hamilton, Oakville, and Winnipeg had significantly higher incidence rates of MF/SS than the national average, as highlighted in Supporting Table 4 ; see online supporting information). This finding is consistent with the above-reported case clustering findings and high CTCL incidence rates in these cities (Fig. 4 and Table 3 ). Furthermore, as mentioned above, we observed that the neighboring cities of Hamilton and Oakville had an important CTCL geographic clustering of cases in industrial areas (Fig. 4F and Supporting Fig. 2 ; see online supporting information). The current MF/SS incidence subanalysis by city supports this trend and further highlights that a significant portion of the industrialized "golden-horseshoe" region of southern Ontario had relatively high incidence rates of MF/SS. Specifically, the golden-horseshoe cities of Oakville, Burlington, Hamilton, and St. Catharines had a high incidence of MF/SS (Supporting Table 4 ; see online supporting information). In contrast, it is important to note that this subanalysis once again confirmed that Ottawa, Ontario, had the lowest MF/SS incidence rate of all major cities in Canada (Supporting Table 4 ; see online supporting information).
Subanalyses of ATLL and ENKL Cases
Although definitive external triggers for MF/SS remain to be identified, human T-cell lymphotropic virus type 1 (HTLV-1) and Epstein-Barr virus (EBV) involvement in the pathogenesis of ATLL and ENKL, respectively, is undeniable. 31, 32 Therefore, we wanted to analyze geographic distributions of these rare lymphomas in our population. During 1992 through 2010, approximately 200 cases of ATLL and approximately 245 cases of ENKL were diagnosed in Canada. We noted that ENKL cases were distributed throughout the country, with higher numbers detected in larger cities (data not shown).
It is noteworthy that an analysis of the distribution for 200 reported cases of ATLL in Canada revealed that, although several patients were distributed in Montreal (30 cases), Toronto (25 cases), Mississauga (5 cases), and Ottawa (5 cases), most of the remaining patients were located in smaller communities. Whereas HTLV-1 infections are rare in Canada, it was reported that HTLV-1 is endemic to Nunavut and other northern territories, where approximately 0.05% of the population is affected by this virus. 33 It is interesting to note that, of the <10 CTCL cases reported in Nunavut from 1992 through 2010, approximately 40% in fact were the ATLL subtype. In contrast, this variant represented only 3% of CTCL cases in Canada. Because of the small sample size, the precise figures/numbers cannot be released. Nevertheless, the out-of-proportion numbers of ATLL in Nunavut are indicative of the role of HTLV-1 in the pathogenesis of this CTCL subtype.
Analysis of CTCL Mortality Across Canada
To further corroborate the incidence trends, we analyzed CTCL-specific mortality using an independent, population-based CVS database. This database records mortality using ICD-9/ICD-10 codes; therefore, we were able to obtain data only for MF and SS variants of CTCL. This analysis further corroborated the MF/SS incidence trend on the provincial and city levels in Canada.
The mortality rate for MF/SS was 0.38 cases per million individuals per year (95% CI, 0.33-0.43 cases per million individuals per year) during 1992 through 2010, as illustrated in Supporting Table 5 (see online supporting information). The rate varied between provinces; however, similar to our CTCL (and specifically MF/SS) incidence results, a trend was observed in which MF/SS mortality rates in New Brunswick and Manitoba were higher than in the rest of Canada (Supporting Table 5A [see online supporting information] and Fig. 5B ). Because the total numbers of patients who died was low in Newfoundland and Labrador, Saskatchewan, Prince Edward Island, and the territories, data for these jurisdictions could not be published to protect patient confidentiality. Supporting Table 5B (see online supporting information) demonstrates that more men (approximately 65%) died from MF/SS and approximately 80% of those patients were aged >60 years. We also observed a trend toward a decrease in overall mortality from MF/SS over time (linear regression slope 5 20.0016; a 0.0016 decrease in mortality rate per year), which was mostly because of an observed decrease in MF mortality (slope 5 20.0017) (Fig. 6 ).
An analysis of mortality rates at the city level specifically highlighted 2 cities in New Brunswick (Moncton and Saint John); Hamilton, Ontario; and Victoria, British Columbia (a popular retirement community in Canada) that had higher CTCL mortality rates than the national average, as indicated in Figure 7 and Supporting Table 6 (see online supporting information). Abbreviations: CI, confidence interval; CTCL, cutaneous T-cell lymphoma. a Cities with statistically significant higher and lower incidence rates compared with the rest of Canada are listed. b All patient numbers are rounded to the nearest 5. c All population numbers are rounded to the nearest thousand.
DISCUSSION
In this study, for the first time, we present a comprehensive analysis of CTCL incidence and mortality across Canada for the years 1992 through 2010 using 3 distinct population-based databases. We analyzed the geographic distribution of CTCL and documented important areas of CTLC case clustering (ie, high-incidence cities and FSAs), where, in several instances, cancer cases were located in industrial parts of Montreal, Hamilton, Oakville, and Winnipeg. It is noteworthy that we also identified areas that were spared by this cancer in cities with a low industrial presence, such as Ottawa (data provided by the CCR database) and Gatineau, Quebec, which is located across the river (data provided by the LRQC database). Like Ottawa, Gatineau is an important administrative center with many federal government offices located in the city. These findings, derived from 2 independent, population-based databases, suggest clinical continuity of our findings for these regions, which span provincial borders. Further analysis of high-incidence FSAs using individual postal codes revealed additional levels of clustering in Winnipeg, Nova Scotia, and in northern Ontario. Specific subanalyses of the incidence of MF, SS, and MTCL NOS, along with MF/SS mortality findings in the eastern provinces and Winnipeg, corroborated our results on CTCL incidence. It is important to note that, once again, this analysis confirmed that Ottawa, Ontario, had the lowest MF/SS incidence rate of all major Canadian cities. Our combined results strongly argue for the existence of external trigger(s) for CTCL and potentially implicate environmental/industrial exposures in the pathogenesis of this cancer. It is noteworthy that previous studies reported 5 exposures that were associated with NHL, including agricultural and food industries; agriculture, hunting, and forestry; manufacturing industries; metallurgy and metalworking; and production and distribution of electricity, gas, and water. 34 Furthermore, exposures to carboxylic acids and peracids, lindane, and potassium oxides in the agriculture, hunting, and forestry industries and exposures to trichloroethylene in manufacturing industries had a moderate association with NHL. 34 These exposures might be important in industrialized cities and in rural communities of Nova Scotia, Newfoundland and Labrador, and New Brunswick.
In particular, the importance of industrial exposures for several Canadian cities cannot be understated. Recent reports in the journals Science and PNAS definitively demonstrated that mice exposed to ambient air near a major highway and 2 integrated steel mills in Hamilton, Ontario, developed high numbers of heritable mutations at repetitive DNA loci. 35, 36 These mutations were not observed in mice that were grown 30 km away in a rural Ontario setting or in mice housed in the same facility near this industrial complex, who were provided with highefficiency particulate air (HEPA)-filtered air. 35, 36 Notably, the L8V FSA located adjacent to these large steel mills in Hamilton, Ontario, had a significantly higher incidence rate of CTCL compared with Ontario and the rest of Canada.
Furthermore, the trends and specific incidence/mortality numbers reported in this study closely mirror the findings for CTCL in the United States. 4, [7] [8] [9] [10] This highlights the continuity of these trends across North America (the United States and Canada). For instance, similar to the United States, in Canada, CTCL affects individuals who are primarily aged >55 years. Also, the majority of individuals affected by this cancer in Canada were men. Finally, consistent with the US data, CTCL was on the rise in Canada until 1998; subsequently, the incidence rate has stabilized at approximately 11 cases per million individuals per year.
It was previously suggested that incidence rates of CTCL are positively correlated with population density, 37 which is generally correlated with the overall physician density and density of dermatologists. An analysis of reported numbers of dermatologists per million individuals per province indicates that there is no significant correlation between the number of dermatologists in a given province and the rates of CTCL incidence (Supporting Table 7 ; see online supporting information). In fact, the most populous province, Ontario, with approximately 200 practicing dermatologists, had the lowest incidence rate of CTCL among the Canadian provinces. Therefore, it is unlikely that the observed low incidence in some provinces, including Ontario and Alberta, can be attributed to a lack of reporting because of the scarcity of dermatologists in these jurisdictions. Moreover, to the best of our knowledge, in Canada, multidisciplinary CTCL clinics/centers of excellence are currently available in Ottawa and Toronto, Ontario; Montreal and Quebec City, Quebec; Edmonton and Calgary, Alberta; and Vancouver, British Columbia. All of these cities have a low or average incidence of CTCL, and specifically MF/SS (Table 3 and  Supporting Table 4 ; see online supporting information). Therefore, it does not appear that a high incidence of this cancer is detected in the proximity of these centers of excellence.
This study had several limitations. There are no data in the described current databases on patients with MF/ CTCL regarding race or clinical stage at the time of diagnosis. It has been established that the age of CTCL onset among African American and Hispanic individuals is significantly earlier (ie, during the 40s vs the 60s among Caucasians). 16 Furthermore, African American men with CTCL are often diagnosed at an advanced clinical stage. 16 Because we did not have this information, we could not confirm these trends in Canada. We also acknowledge that diagnostic criteria for CTCL have evolved over the last 20 years, which may affect CTCL detection, reporting, and incidence. Another important limitation is our inability to present all data because of several federal confidentiality regulations. Although mandatory case rounding does not affect trends in the presented results, suppressed data (because of low numbers) in some cities, provinces, or territories limits our ability to present all the details of CTCL burden in Canada. Also, the inability to report individual patients within specific postal codes does not allow us to present a fully detailed picture of impressive CTCL case clustering in Canada.
In conclusion, we conducted the first ever population-based study using national cancer databases spanning a period of 19 years and provided a large population analysis for this rare malignancy in Canada. This provided statistical power to calculate incidences and mortality rates on multiple levels (province, city, FSA) that were concordant. For the first time, we reported a detailed epidemiologic analysis of CTCL and its subtypes (eg, MF and SS) in the Canadian population and, also for the first time, demonstrated previously unrecognized variations in disease rates between different provinces and cities with impressive, statistically significant findings of geographic clustering of cases as well as areas/cities that were notably spared by CTCL. Such clustering of cases in several instances overlaid heavily industrialized regions in Canada, whereas significant numbers of low-incidence areas were located in Ottawa, Ontario, and similarly low disease rates were observed in the adjacent city of Gatineau, Quebec. This work is fundamental to understanding primary cutaneous lymphomas (and potentially other lymphomas) in North America and further indicates that environmental factors seem to play an important role in the pathophysiology of this skin cancer. The identification of these potentially preventable disease triggers may enable us to decrease incidence, suffering, and deaths from this lymphoma.
